MegaMD Co. Ltd
MegaMD Co., Ltd. engages in the operation of educational institutions in South Korea. The company's education services specialize in infant, elementary, middle, and high school education, as well as adult entrance exams. It is also involved in the operation of online lecture sites; and provision of information services. The company was founded in 2004 and is headquartered in Seoul, South Korea.
MegaMD Co. Ltd (133750) - Total Liabilities
Latest total liabilities as of September 2025: ₩17.46 Billion KRW
Based on the latest financial reports, MegaMD Co. Ltd (133750) has total liabilities worth ₩17.46 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
MegaMD Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how MegaMD Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
MegaMD Co. Ltd Competitors by Total Liabilities
The table below lists competitors of MegaMD Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bayview Acquisition Corp Unit
NASDAQ:BAYAU
|
USA | $5.11 Million |
|
Tron Inc.
NASDAQ:TRON
|
USA | $4.83 Million |
|
WAPS Co. Ltd
KQ:196700
|
Korea | ₩33.63 Billion |
|
Penpower Technology Ltd
TWO:5211
|
Taiwan | NT$45.54 Million |
|
Principal Technologies Inc
V:PTEC
|
Canada | CA$1.57 Million |
|
Shinhwa Contech Co. Ltd
KQ:187270
|
Korea | ₩22.58 Billion |
|
Jialijia Group Corporation Ltd
PINK:RZZN
|
USA | $3.39 Million |
|
Hwail Pharmaceutical Co.Ltd
KQ:061250
|
Korea | ₩5.29 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down MegaMD Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MegaMD Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MegaMD Co. Ltd (2014–2024)
The table below shows the annual total liabilities of MegaMD Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩21.61 Billion | -3.82% |
| 2023-12-31 | ₩22.47 Billion | -19.21% |
| 2022-12-31 | ₩27.81 Billion | -42.03% |
| 2021-12-31 | ₩47.97 Billion | -6.35% |
| 2020-12-31 | ₩51.23 Billion | +0.52% |
| 2019-12-31 | ₩50.96 Billion | +19.61% |
| 2018-12-31 | ₩42.61 Billion | +24.43% |
| 2017-12-31 | ₩34.24 Billion | +19.18% |
| 2016-12-31 | ₩28.73 Billion | -0.43% |
| 2015-12-31 | ₩28.86 Billion | +42.98% |
| 2014-12-31 | ₩20.18 Billion | -- |